Table 1.
Effects of evolocumab on pro- and antiatherogenic lipoproteins
| Study | Population | Duration | Dosing | LDL-C | HDL-C | Non-HDL-C | TGs | ApoB | ApoA1 | Lp(a) |
|---|---|---|---|---|---|---|---|---|---|---|
| Giugliano et al15 (LAPLACE) | Non-FH | 12 weeks | 140 mg Q2W 420 mg Q4W |
−66.1% −50.3% |
8.1% 4.5% |
−61.4% −47.6% |
−33.7% −19.4% |
−56.4% −42.0% |
0.3% 3.6% |
NR NR |
| Robinson et al16 (LAPLACE 2) | Non-FH | 12 weeks | 140 mg Q2W 420 mg Q4W |
−61.8% −65.1% |
8.4% 7.8% |
−54.4% −56.3% |
−9.3% −15.4% |
−49.1% −53.3% |
NR NR |
−25.0% −27.5% |
| Koren et al12 (MENDEL) | Non-FH | 12 weeks | 140 mg Q2W 420 mg Q4W |
−47.2% −52.5% |
10.2% 5.8% |
−45.2% −47.1% |
−12% −3.3% |
−44.2% −42.5% |
10.5% 5.3% |
−29.3% −29.2% |
| Koren et al13 (MENDEL 2) | Non-FH | 12 weeks | 140 mg Q2W 420 mg Q4W |
−57.1% −54.8% |
7.6% 5.5% |
−49.8% −51.2% |
−6.2% −17.7% |
−47.8% −48.4% |
NR NR |
−20.4% −17.8% |
| Blom et al14 (DESCARTES) | Non-FH | 52 weeks | 420 mg Q4W | −59.3% | 5.4% | −50.3% | −11.5% | −44.2% | 2.2% | −22.4% |
| Raal et al21 (RUTHERFORD) | HeFH | 12 weeks | 420 mg Q4W | −56.4% | 6.8% | −53.5% | −19.9% | −46.2% | 1.7% | −31.5% |
| Raal et al24 (RUTHERFORD 2) | HeFH | 12 weeks | 140 mg Q2W 420 mg Q4W |
−59.2% −61.3% |
9.2% 9.1% |
−54.8% −55.0% |
−19.6% −11.6% |
−49.1% −49.4% |
8.7% 3.9% |
−31.6% −28.2% |
| Stein et al23 (TESLA A) | HoFH | 12 weeks | 420 mg Q4W | −16.5%* | 4.7%* | NR | −5.7% | −14.9%* | 1.3%* | −24.6%* |
| Raal et al22 (TESLA B) | HoFH | 12 weeks | 420 mg Q4W | −30.9% | −0.1% | NR | 0.3% | −23.1% | NR | −11.8% |
Notes:
*
Percentage change from baseline (without placebo correction). Percentage changes in lipoprotein subfractions are summarized for evolocumab. Only results for US Food and Drug and Drug Administration-approved regimens are included.
Abbreviations: LDL-C, low-density-lipoprotein cholesterol; HDL-C, high-density-lipoprotein cholesterol; TGs, triglycerides; FH, familial hypercholesterolemia; HeFH, heterozygous FH; HoFH, homozygous FH; NR, not reported; Q2W, every two weeks.